Genomma Lab Internacional Announces Results for the Third Quarter 2025

Core Insights - Genomma Lab reported a challenging third quarter in 2025, with like-for-like sales decreasing by 2.9% due to a weak summer season affecting beverage sales in central Mexico and a softer overall consumption environment [2][3] - Despite the topline pressure, the company maintained a healthy EBITDA margin of 23.7%, reflecting strong business fundamentals and cost containment efforts [2][4] - The productivity program initiated in 2023 is expected to generate cumulative savings of MXN 3.0 billion by 2026, with MXN 1.1 billion already secured this year [2] Financial Performance - Like-for-like sales decreased by 2.9%, primarily due to a tough consumption environment in Mexico and a weak summer season impacting the beverage category, partially offset by growth in Brazil, Chile, Central America, and the Andean cluster [3] - Net sales for Q3 2025 were MXN 4,441.4 million, a decrease of 12.8% compared to Q3 2024 [3] - Gross profit was MXN 2,836.2 million, representing 63.9% of net sales, down from 64.3% in the previous year [3] - EBITDA reached MXN 1,053.6 million, maintaining a margin of 23.7%, with a slight increase of 2 basis points driven by manufacturing cost efficiencies [4] - Net income decreased by 34.2% primarily due to non-cash accumulated hyperinflationary accounting effects related to a 53% depreciation of the Argentine peso [5] Proforma Metrics - Proforma net income decreased by 3.0%, reflecting a strong EBITDA margin and lower net interest expenses [5] - Proforma EPS stood at MXN 0.63 per share, a decrease of 3.0% compared to the previous year [5]